In Vitro Activity of Ceftolozane-Tazobactam against Anaerobic Organisms Identified during the ASPECT-cIAI Study | Zendy

Eliana S. Armstrong | Zendy; David J. Farrell | Zendy; Melissa Palchak | Zendy; Judith N. Steenbergen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In Vitro Activity of Ceftolozane-Tazobactam against Anaerobic Organisms Identified during the ASPECT-cIAI Study

Author(s) -

Eliana S. Armstrong,

David J. Farrell,

Melissa Palchak,

Judith N. Steenbergen

Publication year - 2015

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01964-15

Subject(s) - bacteroides fragilis , metronidazole , anaerobic exercise , microbiology and biotechnology , in vitro , tazobactam , biology , meropenem , anaerobic bacteria , antibiotics , bacteria , biochemistry , physiology , imipenem , antibiotic resistance , genetics

Thein vitro activities of ceftolozane-tazobactam, meropenem, and metronidazole were determined against anaerobic organisms isolated from patients with complicated intraabdominal infections (cIAI) in global phase III studies. Ceftolozane-tazobactam activity was highly variable among different species of theBacteroides fragilis group, with MIC90 values ranging from 2 to 64 μg/ml. More-potentin vitro activity was observed against selected Gram-positive anaerobic organisms; however, small numbers of isolates were available, and, therefore, the clinical significance of these results is unknown. Variable activity of ceftolozane-tazobactam against anaerobic organisms necessitates use in combination with metronidazole for the treatment of cIAI.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research